Sunvozertinib (Synonyms: DZD9008) |
| Catalog No.GC63521 |
Sunvozertinib (DZD9008) es un potente inhibidor de ErbBs (EGFR, Her2, especialmente formas mutantes) y BTK. Sunvozertinib muestra IC50 de 20,4, 20,4, 1,1, 7,5 y 80,4 nM para la inserciÓn NPH del exÓn 20 de EGFR, la inserciÓn ASV del exÓn 20 de EGFR, las mutaciones EGFR L858R y T790M, y Her2 Exon20 YVMA y EGFR WT A431, respectivamente (patente WO2019149164A1, ejemplo 52).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2370013-12-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Sunvozertinib is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52)[1].
Sunvozertinib shows GI50s of 60.4, 83.2, 3.3, 101.3, and 47.1 nM for EGFR exon NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively. Sunvozertinib shows GI50s of 3.2, 5.8, 51.3, and 1983.5 nM for BTK WT OCI-LY-10, BTK WT TMD-8, BTK WT Ri-1, and non-BCR activated DB, respectively[1].Sunvozertinib inhibits p-BTK with IC50 of 1.6 nM[1].
[1]. Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1.
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *